Peyronie’s Disease
New pain or a changing curve? Early assessment matters.
Peyronie’s disease can change over time. Our consultant urologists provide confidential assessment, explain what phase the condition is in and discuss appropriate treatment options.
Prescription-only medicine: treatment options may include Perovial® where clinically appropriate. Perovial® is a prescription-only medicine and is only offered following specialist assessment.
Speak to a specialist if you notice:
- Pain during erections
- A new or changing penile curve
- A firm area or plaque beneath the skin
- Shortening, narrowing or another change in shape
- Difficulty with erections or sexual activity
You do not need to wait for symptoms to settle before arranging an assessment.
Understanding the condition
Peyronie’s disease does not follow exactly the same course in every patient. The condition involves fibrous scar tissue, called plaque, developing within the penis. It may cause pain, curvature, shortening or narrowing and can affect erections, sexual confidence and relationships.
The clinical course is variable. Rather than relying on a fixed number of months, your consultant will use your symptoms, clinical history and examination—and imaging where indicated—to determine whether the condition appears active or stable.
Active phase: symptoms may still be changing
Pain may be present and the curve, plaque or penile shape may still be developing. Treatment decisions are based on the individual clinical picture.
Stable phase: symptoms have stopped changing
Pain often settles and the curvature becomes more consistent. The range of appropriate treatment options may differ from those considered during active disease.
There is no single timetable. The active phase may last many months and is identified from symptoms, clinical history and specialist assessment.
Specialist assessment
A clear diagnosis comes before any treatment decision. Your consultation is designed to establish what has changed, how the condition is affecting you and which options are clinically suitable.
1. Your symptoms
We discuss pain, changes in curvature or shape, erectile function and the effect on sexual activity and wellbeing.
2. Clinical assessment
A consultant examines the plaque and assesses whether the disease appears active or stable.
3. Imaging when needed
Penile ultrasound and a pharmacological erection assessment may be advised to assess anatomy, plaque and blood flow.
What is Perovial®?
Perovial® is a prescription-only medicine containing highly purified hyaluronic acid sodium salt. It is administered in a specialist clinical setting for selected adults with active-phase Peyronie’s disease.
Suitability is determined by a consultant after assessment. Perovial® will not be the right option for every patient, and alternative management may be more appropriate depending on disease phase, plaque characteristics, deformity and individual priorities.
Balanced expectations: clinical studies have assessed pain, curvature, plaque dimensions, erectile function and patient-reported outcomes. The evidence includes relatively small and non-randomised studies with limited follow-up. Individual results vary and no particular outcome can be guaranteed.
Formulation
0.8% hyaluronic acid sodium salt, supplied as 16 mg/2 mL.
Usual course
Weekly appointments over approximately 10–12 weeks, tailored after assessment.
Clinical setting
Administered by an appropriately qualified specialist.
Your treatment journey
Consultant-led care from first assessment to review.
1. Consultation
Discuss symptoms, clinical history and the effect the condition is having on you.
2. Baseline assessment
Examination and any clinically indicated imaging establish a baseline and inform treatment planning.
3. Weekly appointments
If suitable, treatment is normally provided weekly over approximately 10–12 weeks.
4. Clinical review
Your consultant reviews your response and discusses any appropriate next steps.
Safety and aftercare
Your consultant will explain the benefits, limitations, alternatives and risks that apply to you before treatment begins.
Possible short-term effects
Local reactions around the treatment area may occur and are generally temporary.
- Discomfort or tenderness
- Redness or warmth
- Swelling
- Bruising or a small haematoma
Checking suitability
Your consultant will check for reasons why treatment may not be appropriate, including active infection, established calcification, certain deformity patterns or a known sensitivity to an ingredient.
This website is a general overview and is not a substitute for the complete safety information discussed during consultation.
After an appointment: patients are generally advised to avoid sexual activity and vigorous physical activity for 24–48 hours. Follow the individual instructions given by your clinical team and contact them if you are concerned about any reaction.
Treatment costs
Private consultation and treatment fees are shown below. Your consultant will confirm what is clinically appropriate before you decide whether to proceed.
| Item | What is included | Patient price |
|---|---|---|
| Initial specialist Peyronie’s assessment | Consultant assessment, clinical evaluation and treatment planning. | £250–£300 |
| First Perovial® treatment | Medicine, local anaesthetic, treatment consumables and facility costs. If you decide not to proceed with a full programme afterwards, there is no charge for this first treatment. | Complimentary |
| 10-treatment programme | Ten treatments in total, including the complimentary first treatment. Medicine, local anaesthetic, consumables and facility fees throughout. | £4,500 |
| 12-treatment programme | Twelve treatments in total, including the complimentary first treatment. Medicine, local anaesthetic, consumables and facility fees throughout. | £5,000 |
| Post-treatment assessment | Consultant review and assessment of treatment response. | Included |
Complimentary first treatment: this counts as Treatment 1 if you subsequently proceed with a 10- or 12-treatment programme. If you do not continue, there is no charge for that first treatment.
Additional investigations and imaging
Arranged separately where clinically indicated.
| Investigation | Purpose | Price |
|---|---|---|
| Penile ultrasound ± pharmacological erection assessment | Assessment of plaque characteristics, penile anatomy, vascular response and curvature where appropriate. | £300–£400 |
| Repeat penile ultrasound, if required | Repeat objective assessment following treatment where clinically indicated. | £250–£300 |
Your specialists
Assessment and treatment are provided by consultant urological surgeons with specialist expertise in andrology and Peyronie’s disease.
Professor Mark Sullivan
Consultant Urological Surgeon and Associate Professor, University of Oxford.
Mr Musaab Yassin
Consultant Urological Surgeon and Andrologist practising in Oxford and London.
Common questions
How do I know whether the condition is in the active phase?
Pain and a curve or deformity that is still changing can suggest active disease, but there is no single test or fixed timetable. A specialist will assess your symptoms, history and examination findings, with imaging where clinically indicated.
Do I need a referral?
Please contact the clinic directly to ask about current appointment and referral arrangements. The team can explain what information is needed before your consultation.
How long does a Perovial® course take?
If treatment is clinically appropriate, appointments are normally arranged weekly over approximately 10–12 weeks. Your exact plan is confirmed following assessment.
Is a particular result guaranteed?
No. Research has reported changes across several clinical and patient-reported measures, but individual responses vary. Your consultant will discuss realistic expectations, limitations and alternatives in your circumstances.
What should I do after treatment?
You will receive individual aftercare instructions. Patients are generally advised to avoid sexual activity and vigorous physical activity for 24–48 hours and to contact the clinical team if they are concerned about a reaction.
Concerned about pain or a change in shape?
Arrange a confidential consultation to understand what may be happening and discuss the treatment options appropriate for you.
Selected clinical references
- Favilla V, et al. Andrology. 2017;5(4):771–775.
- Cocci A, et al. World Journal of Men’s Health. 2021;39(2):352.
- Zucchi A, et al. Sexual Medicine. 2016;4(2):e85–e90.
Important information: Perovial® is a prescription-only medicine administered by appropriately qualified specialists following clinical assessment. This page provides general information and does not replace individual medical advice. Treatment suitability and prescribing decisions are determined during consultation. No particular outcome is guaranteed. Suspected adverse reactions can be reported through the MHRA Yellow Card scheme.